GLP-1 Drugs: More Than Just Weight Loss

November is Diabetes Awareness Month, highlighting advancements in chronic disease management. GLP-1 medicines, used for diabetes for two decades, have gained prominence for their significant weight loss effects, with newer drugs like semaglutide and tirzepatide inducing substantial reductions. These medications help stimulate insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. Beyond weight loss, they offer benefits for cardiovascular health, kidney disease progression, and fatty liver disease. Many patients report a reduction in cravings and a changed relationship with food. However, responses vary widely, with some individuals experiencing less weight loss than others, particularly those with diabetes. Long-term treatment is often necessary for managing diabetes, severe obesity, or related complications, requiring ongoing medical supervision and monitoring for weight regain. The article stresses that while these drugs are powerful tools, they do not replace the fundamental need for a balanced diet, strength training, and regular medical follow-up to ensure optimal outcomes and manage potential side effects.